Abstract
Synthesis, characterization and cytotoxic activities of ten benzothiazole-piperazine derivatives were reported. In vitro cytotoxic activities of compounds were screened against hepatocellular (HUH-7), breast (MCF-7) and colorectal (HCT-116) cancer cell lines by sulphorhodamine B assay. Based on the GI50 values of the compounds, most of the benzothiazole-piperazine derivatives are active against HUH-7, MCF-7 and HCT-116 cancer cell lines. Aroyl substituted compounds 1h and 1j were found to be the most active derivatives. In addition, further investigation of compounds 1h and 1j by Hoechst staining and FACS revealed that these compounds cause apoptosis by cell cycle arrest at subG1 phase.
Keywords: Anticancer, apoptosis, benzothiazole, cytotoxicity, piperazine, sulphorhodamine B.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis and Anticancer Activity Evaluation of Some Benzothiazole-Piperazine Derivatives
Volume: 15 Issue: 3
Author(s): Enise Ece Gurdal, Ebru Buclulgan, Irem Durmaz, Rengul Cetin-Atalay and Mine Yarim
Affiliation:
Keywords: Anticancer, apoptosis, benzothiazole, cytotoxicity, piperazine, sulphorhodamine B.
Abstract: Synthesis, characterization and cytotoxic activities of ten benzothiazole-piperazine derivatives were reported. In vitro cytotoxic activities of compounds were screened against hepatocellular (HUH-7), breast (MCF-7) and colorectal (HCT-116) cancer cell lines by sulphorhodamine B assay. Based on the GI50 values of the compounds, most of the benzothiazole-piperazine derivatives are active against HUH-7, MCF-7 and HCT-116 cancer cell lines. Aroyl substituted compounds 1h and 1j were found to be the most active derivatives. In addition, further investigation of compounds 1h and 1j by Hoechst staining and FACS revealed that these compounds cause apoptosis by cell cycle arrest at subG1 phase.
Export Options
About this article
Cite this article as:
Gurdal Ece Enise, Buclulgan Ebru, Durmaz Irem, Cetin-Atalay Rengul and Yarim Mine, Synthesis and Anticancer Activity Evaluation of Some Benzothiazole-Piperazine Derivatives, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (3) . https://dx.doi.org/10.2174/1871520615666141216151101
DOI https://dx.doi.org/10.2174/1871520615666141216151101 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets Drug-Membrane Interactions: Significance for Medicinal Chemistry
Current Medicinal Chemistry Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease
Current Drug Targets Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Epigenetic Regulation of Gene Expression as an Anticancer Drug Target
Current Cancer Drug Targets Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer
Current Molecular Medicine Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy